Evaluation of paraoxonase 1 arylesterase activity and lipid peroxide levels in patients with type 1 diabetes

Polskie Archiwum Medycyny Wewnetrznej

Volumn 121, Issue 12, 2011, Pages 448-455

  Wegner, Małgorzata ^a   Pioruńska Stolzmann, Maria ^a   Araszkiewicz, Aleksandra ^a   Zozulińska Ziołkiewicz, Dorota ^a   Wierusz Wysocka, Bogna ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Late diabetic complications; Lipid peroxide; Oxidative stress; Paraoxonase 1; Type 1 diabetes

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; ARYLESTERASE; LIPID PEROXIDE;

ADULT; ARTICLE; ASSAY; BODY MASS; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETIC PATIENT; ENZYME ACTIVITY; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LIPOGENESIS; MAJOR CLINICAL STUDY; MALE; METABOLISM; PARAMETERS; PROTEIN BLOOD LEVEL; SPECTROPHOTOMETRY;

EID: 84855273721     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: 10.20452/pamw.1113     Document Type: Article

References (38)

1. Kuyvenhoven JP, Meinders AE. Oxidative stress and diabetes mellitus: pathogenesis of long-term complications. Eur J Intern Med. 1999; 10: 9-19. (Pubitemid 29229660)
2. Kanter JE, Johansson F, LeBoeuf RC, Bornfeldt KE. Do glucose and lipids exert independent effects on atherosclerotic lesion initiation or progression to advanced plaques? Circ Res. 2007; 100: 769-781. (Pubitemid 46555682)
3. Szypowska A, Golicki D, Groela L, Pańkowska E. Long-acting insulin analoque detemir compared with NPH insulin In type 1 diabetes. Pol Arch Med Wewn. 2011; 121: 237-246.
4. Wolffenbuttel BH, van Haeffen TW. Prevention of complications in noninsulin- dependent diabetes mellitus (NIDDM). Drugs. 1995; 50: 263-288.
5. Marcovecchio ML, Dalton RN, Prevost AT, et al. Prevalence of abnormal lipid profiles and the relationship with the development of microalbuminuria in adolescent with type 1 diabetes. Diabetes Care. 2009; 32: 658-663.
6. Vergès B. Lipid disorders in type 1 diabetes. Diabetes Metab. 2009; 35: 353-360.
7. Gallo LM, Silverstein JH, Shuster JJ, Haller MJ. Arterial stiffness, lipoprotein particle size, and lipoprotein particle concentration in children with type 1 diabetes. J Pediatr Endocrinol Metab. 2010; 23: 661-667.
8. Bustos P, Radojkovic C, Ulloa N, et al. Lipoprotein composition in children and adolescents with type 1 diabetes mellitus. J Pediatr Endocrinol Metab. 2005; 18: 257-264. (Pubitemid 40425561)
9. Bomefont-Rousselot D, Bastard JP, Joudon MC, Delattre J. Consequences of the diabetic status on the oxidant/antioxidant balance. Diabetes Metab. 2000; 26: 163-176.
10. Wegner M, Araszkiewicz A, Piorunska-Mikolajczak A, et al. The evaluation of IL-12 concentration, PAF-AH and PLA(2) activity in patients with type 1 diabetes treated with intensive insulin therapy. Clin Biochem. 2009; 42: 1621-1627.
11. Craig ME, Hettersley A, Donaghue KC. Definition, epidemiology and classification of diabetes in children and adolescents. Pediatr Diabetes. 2009; 10 Suppl 12: 3-12.
12. Podrez EA. Anti-oxidant properties of high-density lipoprotein and atherosclerosis. Clin Exp Pharmacol Physiol. 2010; 37: 719-725.
13. Perla-Kajan J, Jakubowski H. Paraoxonase 1 protects against protein n-homocysteinylation in humans. FASEB J. 2010; 24: 931-936.
14. Mackness B, Durrington PN, Boulton AJ, et al. Serum paraoxonase activity in patients with type 1 diabetes compared to healthy controls. Eur J Clin Invest. 2002; 32: 259-264. (Pubitemid 36216591)
15. Mackness B, Hine D, McElduff P, Mackness M. High C-reactive protein and low paraoxonase 1 in diabetes as risk factor for coronary heart disease. Atherosclerosis 2006; 186: 396-401.
16. Abbott CA, Mackness MI, Kumar S, et al. Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Artherioscler Thromb Vasc Biol. 1995; 15: 1812-1818.
17. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 1997; 20: 1183-1197.
18. Araszkiewicz A, Zozulinska-Ziolkiewicz D, Trepinska M, Wierusz-Wysocka B. Knowledge after five-day teaching program in intensive insulin therapy performer AT the onset of the type 1 diabetes influences the development of late diabetic complications. Diab Res Clin Pract. 2008; 81: 61-67.
19. Jeppsson J, Kobold V, Barr J, et al.; International federation of clinical chemistry and laboratory medicine (IFCC). Approved IFCC reference method for the measurement of HbA1c in human blood. Clin Chem Lab Med. 2002; 40: 78-79.
20. Mihaljević B, Katusin-Razem B, Razem D. The reevaluation of the ferric thiocyanate assay for lipid hydroperoxides with special consideration of the mechanistic aspects of the response. Free Radic Biol Med. 1996; 21: 53-63. (Pubitemid 26230405)
21. Gan K, Smolen A, Eckerson H, La Du BN. Purification of human serum paraoxonase/ arylesterase. Evidence for one esterase catalyzing both activities. Drug Metab Dispos. 1991; 19: 100-106.
22. Emerging Risk Factors Collaboration; Di Angelantonio E, Sarwar N, Perry P, et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009; 302: 1993-2000.
23. Mackness MI, Arrol S, Durrington PN. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett. 1991; 286: 152-154.
24. Valabhji J, McColl AJ, Schachter M, et al. High-density lipoprotein composition and paraoxonase activity in type 1 diabetes. Clin Sci (Lond). 2001; 101: 659-670. (Pubitemid 33135348)
25. Shao B, Heineke JW. HDL, lipid peroxidation, and atherosclerosis. J Lipid Res. 2009; 50: 716-722.
26. Karlhuber GM, Bauer HC, Eckl PM. Cytotoxic and genotoxic effects of 4-hydroxynonenal in cerebral endothelial cells. Mutat Res. 1997; 381: 209-216. (Pubitemid 28015416)
27. Flekac M, Skrha J, Zídková K, et al. Paraoxonase 1 gene polymorphisms and enzyme activities in diabetes mellitus. Physiol Res. 2008; 57: 717-726.
28. Nowak M, Wielkoszyński T, Marek B, et al. Antioxidant potential, paraoxonase 1, ceruloplasmin activity and C-reactive protein concentration in diabetic retinopathy. Clin Exp Med. 2010; 10: 185-192.
29. Hedrick CC, Thorpe SR, Fu MX, et al. Glycation impairs high-density lipoprotein function. Diabetologia. 2000;43: 312-320. (Pubitemid 30163474)
30. Mastorikou M, Mackness B, Liu Y, Mackness M. Glycation of paraoxonase-1 inhibits its activity and impairs the ability of high-density lipoprotein to metabolize membrane lipid hydroperoxides. Diabet Med. 2008; 25: 1049-1055.
31. Wu B, Fukuo K, Suzuki K, et al. Relationships of systemic oxidative stress to body fat distribution, adipokines and inflammatory markers in healthy middle-aged women. Endocr J. 2009; 56: 773-782.
32. Kordonouri O, James RW, Bennetts B, et al. Modulation by blood glucose levels of activity and concentration of paraoxonase in young patients with type 1 diabetes mellitus. Metabolism. 2001; 50: 657-660. (Pubitemid 32551818)
33. Kao YL, Donaghue K, Chan A, et al. A variant of paraoxonase (PON1) gene is associated with diabetic retinopathy in IDDM. J Clin Endocrinol Metab. 1998; 83: 2589-2592. (Pubitemid 28503069)
34. Rozenberg O, Rosenblat M, Coleman R, et al. Paraoxonase (PON1) deficiency is associated with increased macrophage oxidative stress: studies in PON1-knockout mice. Free Radic Biol Med. 2003; 34: 774-784. (Pubitemid 36288542)
35. Bloomer RJ, Fisher-Wellman KH. Systemic oxidative stress is increased to a greater degree in young, obese women following consumption of a high fat meal. Oxid Med Cell Longev. 2009; 2: 19-25.
36. Wu B, Fukuo K, Suzuki K, et al. Relationships of systemic oxidative stress to body fat distribution, adipokines and inflammatory markers in healthy middle-aged women. Endocr J. 2009; 6: 773-782.
37. Aslan M, Horoz M, Sabuman T, et al. Serum paraoxonase enzyme activity and oxidative stress in obese subjects. Pol Arch Med wewn 2011; 121: 181-186.
38. Correze C, Krug E, Verhaegen M, Nunez J. Regulation of lipogenesis in adipocytes independent effects of thyroid hormones, cyclic AMP and insulin on the uptake of deoxy-D-glucose. Biochim Biophys Acta. 1979; 574: 164-172. (Pubitemid 9244665)